Markets
Companies price increases earnings
(CSA Archives/Getty Images)

With earnings season done, we know what companies are thinking

They want to raise prices. That’s a bad sign for inflation, but also a reminder of why stocks are “the best of all the poor alternatives” for investors when prices surge.

8/28/25 1:56PM

Here’s one big takeaway from the more or less complete Q2 earnings season: Corporate America is trying to pass along rising costs from the Trump administration’s tariffs in the form of higher prices.

Recent notes from analysts at both Morgan Stanley and Goldman Sachs spotlighted an uptick in chatter about price hikes during the six-week flurry of quarterly reports that essentially concluded yesterday, with AI chip giant Nvidia’s numbers.

“Tariffs have begun to weigh on margins,” wrote Goldman Sachs analysts in a note published this week. “And companies are using a variety of strategies, including renegotiating contracts with suppliers and raising consumer prices, to mitigate the impact.”

Goldman Sachs Price Chart
(Goldman Sachs)

Morgan Stanley market watchers saw the same dynamic at play, writing that during earnings season companies laid out a range of options to offset or reduce the tariff-related costs.

“Corporate America is adapting on multiple fronts (pricing, supply chain, and cost control) to cushion the impact of higher import tariffs,” they wrote. “The full effect is not yet evident and we continue to expect more firmness in goods inflation.”

They also noted that several recent, forward-looking surveys of executives suggest they intend to keep the price increases coming.

Morgan Stanley Price Increase Intentions
(Morgan Stanley)

As both research shops make clear, price increases aren’t the only tool that companies are using to offset the rising impact of tariffs.

But they are a prominent one, which matters.

It’s another strong piece of evidence that the near mythical tariff-related inflation that economic wonks have been warning about for months — but which has never quite materialized — actually remains a real economic risk.

boxes on conveyor belt
Inputs are getting pricey (Getty Images)

Producer price index highlights more risk

That’s a similar story to the one told by the most recent report on the producer price index, which measures the prices companies pay their suppliers and is considered a proxy for inflation before it reaches consumers.

When the PPI numbers came out a couple weeks back, they showed showed much higher-than-expected annual PPI inflation of 3.3% in July.

As a result, economists have since raised their expectations for the Fed’s preferred gauge of consumer price inflation in July (due out Friday morning) to 2.9%, nearly a full point above the Fed’s target of 2%.

In short, there’s a lot of evidence out there that inflation risks are building.

At the same time, the Fed, after weeks of attacks on its long-established political independence — including the Trump administration’s current attempt to dismiss key Fed official Lisa Cook — seems all but certain to cut rates at its meeting next month anyway.

(Quick aside: the last time the Fed bowed to clear political pressure like this, it helped fuel the inflationary problems of the early 1970s.)

So, what happens to stocks if we get another inflationary flare-up?

Typically, you’d expect the Fed to start raising interest rates, which tends to provide a gut punch to equity prices. That was the story of 2022, when the S&P 500 dropped 19%.

But in President Trump’s America, with a Federal Reserve potentially taking cues from the White House, it’s less certain that the Fed’s response to high inflation will be typical.

Perhaps the Fed will allow much higher inflation than it has targeted in recent decades, leaving short-term interest rates lower than expected and inflation burning much hotter.

That’s not an ideal backdrop for investment. But in such a world, stocks still might be your best bet.

That’s because owning shares of companies that can actually raise prices provides some protection for investors, and is far better than options like owning bonds or sticking your cash in the bank, where inflation erodes its value.

As a sprightly, 47-year-old Warren Buffett told Fortune magazine back 1977, amid the raging inflation of that era: “Stocks are probably still the best of all the poor alternatives in an era of inflation.”

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.